Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort.
Barnabas GellenNathalie Thorin-TrescasesEric ThorinElise GandPhilippe SosnerSonia BrishoualVincent RigalleauDavid MontaigneVincent JavaugueYann PucheuPhilippe GataultXavier PiguelSamy HadjadjPierre-Jean Saulniernull nullPublished in: Diabetologia (2020)
In individuals with type 2 diabetes, increased serum TN-C concentrations were independently associated with death and MACE. Therefore, including TN-C as a prognostic biomarker could improve risk stratification in these individuals.